Replies to post #44811 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

UK only requires 6 unit output per day for GBM. (On average)

At 2,200 units per year, if a production facility completed about 6 patient (eight day) runs per day, they would produce enough DCVax-L to cover all the GBM cases in Great Britain per year.

At 3,300 units per year, a German production facility would need to complete about 9 patient (eight day) runs per day to cover all the GBM cases per year in Germany.

At 13,000 units per year, a USA production facility would need to complete about 36 patient (eight day) runs per day for GBM.

The expansions occurring at King's College, Fraunhofer and Cognate are likely sufficient to handle this demand, and they are likely capable of handling broader demand wherein brain gliomas beyond GBM may be subject to treatment.

[flipper44]

With everything we've learned from recent events.

1. 30 million announced on October 21.
2. ONDRA perhaps meeting with NWBO about that time -- possibly before that time.
3. Short attack on October 16.
4. DCVax-L update to active, not recruiting October 29, 2015 -- which means the entry was made a few days before that....perhaps October 26....
5. Thwarted attempt? at hostile takeover? Late November to Early December.

It may be best to review what was a fact on Ocober 28, 2015:

Detailed negotiations are now underway to build on a contract (>£2M per annum) for the CTU to serve as a manufacturing hub for the production of DCVax-L and its broader use at multiple other facilities in UK and other European Centres. -- www.ecmcnetwork.org.uk/news/announcement/kings-college-hospital-lead-dcvas-l-study

Does anyone think that might bring out some aggressive wolves licking their chops over NWBO? I do.